MilliporeSigma Expands cGMP Facility

May 2, 2016
BioPharm International Editors

MilliporeSigma, the North American life-sciences business of Germany’s Merck KGaA, added a 2000-L single-use bioreactor to its facility in Massachusetts.

MilliporeSigma expanded its single-use cGMP facility with the addition of the Mobius 2000-L single-use bioreactor, the company announced May 2, 2016. With the new upstream suite at its biodevelopment center in France, MilliporeSigma can now offer clients full process-line cGMP manufacturing, comprised of MilliporeSigma's own instrumentation and products.

"Our aim is to facilitate accelerated drug development and delivery via continued innovation and technical expertise by offering customers a complete end-to-end solution from clone to commercial production," said Udit Batra, CEO, MilliporeSigma, in the press release.

With this increase in scale and scope, MilliporeSigma can advance clients' recombinant products from cell-line development through to late-stage clinical production. At the point of tech transfer out to a contract manufacturing organization or other facility, clients can also leverage MilliporeSigma's Provantage End-to-End Services available worldwide to mitigate the risks traditionally associated with upscaling to commercial production. These services include process development, cGMP manufacturing, facility design, manufacturing equipment and consumables, process and equipment training, technology transfer, and set-up for commercialization.

Merck KGaA, Darmstadt, Germany operates in the US and Canada as EMD Serono in healthcare, MilliporeSigma in life sciences, and EMD Performance Materials.

Source: MilliporeSigma